Cargando…

The Efficacy of Bevacizumab Compared with Other Targeted Drugs for Patients with Advanced NSCLC: A Meta-Analysis from 30 Randomized Controlled Clinical Trials

BACKGROUND: The extent of the benefit of bevacizumab combined with chemotherapy in the treatment of advanced non-small-cell lung cancer (NSCLC) is still unclear. We performed this meta-analysis to compare the efficacy of bevacizumab with other commonly used targeted drugs for different patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, Jianlan, Cai, Xueya, Zhu, Min, Liu, Tianshu, Zhao, Naiqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3628504/ https://www.ncbi.nlm.nih.gov/pubmed/23614008 http://dx.doi.org/10.1371/journal.pone.0062038

Ejemplares similares

c-Met as a Prognostic Marker in Gastric Cancer: A Systematic Review and Meta-Analysis
por: Yu, Shan, et al.
Publicado: (2013)

Efficacy and safety of adding bevacizumab biosimilar or original drug to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC: a systematic review and meta-analysis
por: Yang, Liu, et al.
Publicado: (2022)

Specific Safety Profile of Bevacizumab in Asian Patients With Advanced NSCLC: A Meta-Analysis
por: Chen, Zhenguang, et al.
Publicado: (2015)

Consideration in Selection of the Control Group in Diagnostic Tests
por: Cui, Jianlan, et al.
Publicado: (2012)

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
por: Sakharkar, Prashant, et al.
Publicado: (2023)

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis
por: Dai, Jiali, et al.
Publicado: (2019)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC
por: Li, Butuo, et al.
Publicado: (2018)

Bevacizumab in the treatment of NSCLC: patient selection and perspectives
por: Russo, Alessia E, et al.
Publicado: (2017)

The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen
por: Geng, Nan, et al.
Publicado: (2021)

Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study
por: Zhao, Zhiting, et al.
Publicado: (2023)

Laboratory Parameters are Possible Prognostic Markers in Patients with Advanced-stage NSCLC Treated with Bevacizumab plus Chemotherapy
por: Svaton, Martin, et al.
Publicado: (2021)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study
por: Zhou, Chun-Hua, et al.
Publicado: (2021)

Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases
por: Tian, Yaru, et al.
Publicado: (2019)

The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis
por: Zhou, Liang, et al.
Publicado: (2016)

Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
por: Yi, Lilan, et al.
Publicado: (2019)

Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression
por: Xu, Ziyi, et al.
Publicado: (2022)

Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC
por: Cui, Pengfei, et al.
Publicado: (2020)

Integrated multi-dimensional deep neural network model improves prognosis prediction of advanced NSCLC patients receiving bevacizumab
por: Li, Butuo, et al.
Publicado: (2023)

Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)
por: Chien, Chun-Ru, et al.
Publicado: (2012)

Pharmacogenetic Association between XRCC1 Polymorphisms and Response to Platinum-Based Chemotherapy in Asian Patients with NSCLC: A Meta-Analysis
por: Zhang, Ningning, et al.
Publicado: (2020)

The impact of histological types on the efficacy of angiogenesis inhibitors in the treatment of advanced NSCLC: a meta-analysis of randomized controlled trials
por: Zhang, Jian, et al.
Publicado: (2015)

Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
por: Jantus-Lewintre, Eloisa, et al.
Publicado: (2021)

Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis
por: Botrel, Tobias Engel Ayer, et al.
Publicado: (2016)

Efficacy and Safety of Bevacizumab in the Treatment of Pterygium: An Updated Meta-Analysis of Randomized Controlled Trials
por: Sun, Yi, et al.
Publicado: (2018)

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017)

Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review
por: Yu, Da-Ping, et al.
Publicado: (2017)

A meta-analysis of the safety and effectiveness of pemetrexed compared with gefitinib for pre-treated advanced or metastatic NSCLC
por: Lu, Xiaoxin, et al.
Publicado: (2020)

Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis
por: Chen, Hui, et al.
Publicado: (2021)

Focus on Nintedanib in NSCLC and Other Tumors
por: Manzo, Anna, et al.
Publicado: (2016)

Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC
por: Kim, Edward S., et al.
Publicado: (2021)

Paclitaxel–bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study
por: Bilger, Geoffroy, et al.
Publicado: (2022)

Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts
por: Vlahovic, G, et al.
Publicado: (2007)

Comparative efficacy of Chinese herbal injections combined with GP regimen chemotherapy for patients with advanced NSCLC: A protocol for systematic review and network meta-analysis
por: Li, Juan, et al.
Publicado: (2020)

Comparative efficacy of 10 Chinese herbal injections combined with GP regimen chemotherapy for patients with advanced NSCLC a systematic review and network meta-analysis
por: Li, Juan, et al.
Publicado: (2022)

Immunotherapeutic Advances for NSCLC
por: Massafra, Marco, et al.
Publicado: (2021)

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Zhang, Shu, et al.
Publicado: (2016)

Clinical Efficacy and Safety of Bevacizumab, Apatinib, and Recombinant Human Endothelial Inhibitor in the Treatment of Advanced Gastric Cancer
por: Wang, Liang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7jkr5hduip1peh7sfkn2upkmim